Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose

Area of Science:

• Biotechnology
• Protein Chemistry
• Cancer Therapeutics

Background:

• Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is crucial in cancer treatment.
• Current purification methods rely on expensive Protein A affinity chromatography.
• There is a need for more stable and cost-effective purification ligands.

Purpose of the Study:

• To synthesize and evaluate a novel peptide ligand, Ac-PHQGQHIGVSK, for bevacizumab purification.
• To compare the performance of the peptide ligand with Protein A in affinity chromatography.
• To assess the stability and cost-effectiveness of the new purification strategy.

Main Methods:

• Solid-phase peptide synthesis of Ac-PHQGQHIGVSK.
• Immobilization of the peptide onto agarose beads.
• Affinity chromatography purification of bevacizumab from CHO cell culture supernatant.
• Analysis of binding capacity, selectivity, and integrity of purified bevacizumab.

Main Results:

• Ac-PHQGQHIGVSK-agarose demonstrated equivalent capacity and selectivity to Protein A matrices.
• The peptide ligand exhibited enhanced stability due to the absence of oxidation-prone amino acids (Trp, Met, Cys).
• Purification under mild conditions successfully preserved the integrity of bevacizumab.

Conclusions:

• The Ac-PHQGQHIGVSK peptide ligand presents a viable, stable, and economical alternative to Protein A for bevacizumab purification.
• This novel approach can reduce manufacturing costs for bevacizumab production.
• The peptide ligand's stability ensures a longer useful life for the chromatographic matrix.